室外夜间暴露于光线 (光污染) 与阿尔茨海默病相关
Robin M Voigt1,2,3, Bichun Ouyang4, Ali Keshavarzian1,2,3,5
1Rush Medical College, Rush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, IL, United States.
Frontiers in neuroscience
|September 23, 2024
概括
增加夜间光线暴露与更高的阿尔茨海默病 (AD) 患病率有关. 这种环境因素,晚上的人工光,显示出与阿尔茨海默氏症有着显著的关联,特别是在年轻人中.
科学领域:
- 环境健康 环境健康
- 神经科学是一个神经科学.
- 流行病学 流行病学
背景情况:
- 全球范围内阿尔茨海默病 (AD) 的患病率正在上升.
- 延长寿命和环境因素有助于AD.
- 夜间人工照明 (ALAN) 是一个新兴的环境问题.
研究的目的:
- 调查室外夜间照明暴露与美国阿尔茨海默病患病率之间的联系.
- 为了比较夜间暴露于光线的影响与其他已知的阿尔茨海默病风险因素.
主要方法:
- 利用卫星获取的户外夜间光强度数据.
- 雇佣的医疗保险数据来确定AD的流行率.
- 在不同的人口和疾病群体中进行了光照和AD患病率之间的相关性分析.
主要成果:
- 较高的室外夜间光强度与AD患病率的增加有显著的关联.
- 夜间光线强度与阿尔茨海默病的关联比其他一些并发症更强,包括滥用酒精,慢性病,抑郁症,心力衰竭和肥胖.
- 夜间光和AD之间的关联在65岁以下的个体中尤为明显,超过了其他检查的疾病因素的关联强度.
结论:
- 研究结果表明,在夜间接触人工光线可能对阿尔茨海默病产生重大环境影响.
- 需要进一步的研究,以阐明光污染与AD病原体之间的联系机制.
- 公共卫生战略可能需要考虑光污染对神经退行性疾病的影响.
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Photoreceptors and Visual Pathways
5.9K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
5.9K
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170


